Literature DB >> 19026506

Effectiveness of the antibiotic lock therapy for the treatment of port-related enterococci, Gram-negative, or Gram-positive bacilli bloodstream infections.

Jose L Del Pozo1, Marta Alonso, Alicia Serrera, Silvia Hernaez, Aitziber Aguinaga, Jose Leiva.   

Abstract

OBJECTIVE: The purpose of this study is to evaluate the efficacy of antibiotic lock therapy to treat port-related enterococci, Gram-negative, or Gram-positive bacilli bloodstream infections. PATIENTS AND METHODS: We conducted a prospective observational study including all patients with port-related bacteremia diagnosed at the Clinica Universitaria de Navarra, Pamplona, Spain. During a 36-month period, 110 patients were diagnosed with port-related bacteremia. Of these patients, 18 met criteria to be enrolled in the study. They were treated with a combination of systemic and antibiotic lock therapy (12-24 h/day during 7-14 days). Treatment effectiveness was assessed by clinical and microbiologic criteria.
RESULTS: Treatment was associated with clinical and microbiologic success in 88.8% of our patients (2/2 of the Propionibacterium acnes, 5/5 of the Corynebacterium spp., 6/7 of the Gram-negative bacillus, and 3/4 of the Enterococcus faecium port-related bloodstream infections). Mean increase of port life span for all patients after bacteremia was 288 days (range, 0-1403 days).
CONCLUSION: Antibiotic lock therapy combined with systemic antibiotics appears to be a safe and effective treatment of port-related bacteremia caused by enterococci, Gram-negative, or Gram-positive bacilli if the patient is stable and no septic syndrome is associated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19026506     DOI: 10.1016/j.diagmicrobio.2008.10.004

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  8 in total

1.  In Vitro Study To Evaluate the Bioactivity of Freezing a Heparin-Based Dalbavancin Lock Solution.

Authors:  Marta Rubia; Andrea Cordero; María Jesús Pérez-Granda; Emilia Cercenado; Cristina Pascual; Patricia Muñoz; María Guembe
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

Review 2.  Antimicrobial lock therapy in central-line associated bloodstream infections: a systematic review.

Authors:  Matteo Vassallo; Brigitte Dunais; Pierre-Marie Roger
Journal:  Infection       Date:  2015-02-06       Impact factor: 3.553

3.  Activity of ethanol and daptomycin lock on biofilm generated by an in vitro dynamic model using real subcutaneous injection ports.

Authors:  C Aumeran; P Guyot; M Boisnoir; C Robin-Hennequin; M Vidal; C Forestier; O Traore; O Lesens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-10-19       Impact factor: 3.267

4.  Current strategies for the prevention and management of central line-associated bloodstream infections.

Authors:  Zhuolin Han; Stephen Y Liang; Jonas Marschall
Journal:  Infect Drug Resist       Date:  2010-11-23       Impact factor: 4.003

5.  S-Nitroso-N-acetyl-l-cysteine Ethyl Ester (SNACET) Catheter Lock Solution to Reduce Catheter-Associated Infections.

Authors:  Rajnish Kumar; Hamed Massoumi; Manjyot Kaur Chug; Elizabeth J Brisbois
Journal:  ACS Appl Mater Interfaces       Date:  2021-05-24       Impact factor: 10.383

Review 6.  Antibiotic lock therapy: review of technique and logistical challenges.

Authors:  Julie Ann Justo; P Brandon Bookstaver
Journal:  Infect Drug Resist       Date:  2014-12-12       Impact factor: 4.003

7.  A Dalbavancin Lock Solution Can Reduce Enterococcal Biofilms After Freezing.

Authors:  Marta Díaz-Navarro; Rama Hafian; Irene Manzano; María J Pérez-Granda; Emilia Cercenado; Cristina Pascual; Carmen Rodríguez; Patricia Muñoz; María Guembe
Journal:  Infect Dis Ther       Date:  2022-01-16

Review 8.  Long-term catheterization: current approaches in the diagnosis and treatment of port-related infections.

Authors:  Cesar Bustos; Aitziber Aguinaga; Francisco Carmona-Torre; Jose Luis Del Pozo
Journal:  Infect Drug Resist       Date:  2014-02-18       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.